The CAR-T cell therapy market was valued at US$ 72.0 Mn in 2017 and is projected to exhibit a double-digit compound annual growth rate (CAGR) of 51.1% during the forecast period from 2018 to 2026. Scientists have encountered the biggest challenge in treating cancer: the cancer cells with the disease progression usually become invisible to the body’s defense mechanism. Immunotherapy is the future in treating cancer, where the immune cells are genetically engineered to recognize the biomarkers of cancerous cells, target them, and kill them. CAR-T cell therapy does not kill normal healthy cells and has proven effective in relapsed cancer treatment. The CAR-T cell therapy market is driven by factors such as cancer's rising prevalence, growing immune-oncology research, and massive funding from government health institutions and pharma giants in CAR-T cell therapy development. The traditional approach adopted for the treatment of leukemia was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection, and chemotherapy to kill the leukemia cells in the bone marrow. However, advances in cell therapy and gene therapy have rendered the development of oncology treatment by the body’s immune system. The FDA-approved CAR-T cell therapy is Axicabtagene ciloleucel (Yescarta) and Tisagenleucel (Kymriah),). Currently, CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. There are more than 2,000 candidates in the clinical trials for different cancer indications.
Market Synopsis
Growing Research and Development of CAR-T to Drive the Market Growth
CD 19 antigens are currently being studied extensively to prove their efficacy in the treatment of acute lymphoblastic leukemia. The rising prevalence of acute lymphoblastic leukemia in children and adults has buttressed the dominance of CD 19 antigens for cancer therapy. Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) are the two approved CD19 therapies and the only CAR-T cell therapies currently approved in the market. In addition, CD 22 and CD 30 antigens are being studied diligently in the preclinical trials with promising results for the treatment of B cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma, respectively.
Rising Prevalence of Blood Cancers to Augment the Growth of CAR-T Cell Therapy Market
The non-Hodgkin’s lymphoma segment dominated the market in 2017 owing to a surge in the number of NHL cases coupled with the higher adoption of YESCARTA (axicabtagene ciloleucel) Kymriah (tisagenlecleucel, formerly CTL019) around the world. CAR T cell therapy products are currently only indicated in non-Hodgkin’s lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia. However, clinical trials of some CAR T cell therapy drugs being studied (under study) for the treatment of multiple myeloma, acute myeloid leukemia, melanoma, glioblastomas, myelodysplastic syndromes (MDS), and cancer of pancreatitis, prostate, bladder, esophagus, stomach, liver, lung, kidney, & cervix. Thus, proliferating application of CAR-T in various indications would further boost the market during the forecast period.
Increasing Adoption of CAR-T Cell Therapy in North America will Drive Swift Growth during the Forecast Period.
In 2017, North America demonstrated supremacy in the global CAR-T cell therapy market owing to the exclusive availability of the two approved products, Kymriah (Novartis AG) and Yescarta (Gilead Sciences, Inc.). Developed healthcare infrastructure, high accessibility to advanced therapies, rise in healthcare expenditure, incessant investment in R&D activities, and presence of established market leaders further catalyze the overall market growth in this region. With Medicare constantly working on structuring suitable reimbursement policies for dynamically priced CAR-T cell therapies, the demand for it is projected to increase during the forecast period. In the Asia Pacific, the market entry of Kymriah is expected by the end of 2018 in Japan. The extensive pipeline portfolio for CAR-T cell therapy in China and the continuous growing cancer prevalence in Asia Pacific regions predominantly contribute to the maximum growth.
Historical & Forecast Period
2016 – Historical Year
2017 – Base Year
2018-2026 – Forecast Period
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The CAR-T cell therapy market report furnishes quantitative analysis and its latest market trends. The market is segmented based on antigen type, indication, and geography.
By Antigen Type (2016–2026; US$ Mn)
CD 19
Pipeline Analysis (Qualitative Analysis)
CD 20
CD 22
CD 30
CD 33
GD 2
HER 2
MESO
EGFRvIII
By Indication (2016–2026; US$ Mn)
Non-Hodgkin’s Lymphoma
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Geography Segment (2016–2026; US$ Mn)
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Russia
Rest of Europe
Asia-Pacific
India
China
Japan
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC Countries
South Africa
Rest of Middle East and Africa
Market is studied in order to understand the current and future market trends in the CAR-T cell therapy market. The market is estimated by providing the compounded annual growth rate (CAGR) and data forecast from 2018 to 2026. In addition, strategic acquisition, merger, and collaboration among the key players for developing innovative product pipelines are mentioned in the business strategy section. The key players currently engaged in the CAR-T cell therapy market are Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Juno Therapeutics, Cellectis, Eureka Therapeutics, Kite Pharma, Sorrento Therapeutics and Novartis AG, Gilead Sciences among others.
Key questions answered in this report
How will the global CAR-T cell therapy market perform during the forecast period from 2018 to 2026?
What are the latest trends in the CAR-T cell therapy market and valuable opportunities for key players?
Who are the leading players in the global CAR-T cell therapy market?
Which is the leading/fastest region in the global CAR-T cell therapy market?
Currently, what are the reimbursement scenario and regulatory structure for CAR-T cell therapy?
What are the drivers and restraints governing the global CAR-T cell therapy market?
What is the pipeline scenario of the global CAR-T cell therapy market?
Which indications are being targeted using CAR-T cell therapy?
What is the status of the clinical trials studied for various antigens?
Frequently asked questions :
The market for CAR-T Cell Therapy Market is expected to reach US$ XX Bn in 2026.
The CAR-T Cell Therapy Market is expected to see significant CAGR growth over the coming years, at 51.1%.
The report is forecasted from 2017-2026.
The base year of this report is 2017.
Bellicum Pharmaceuticals, Inc., Celgene Corporation, Cellectis, Eureka Therapeutics, Inc., Immune Therapeutics, Inc. are some of the major players in the global market.
